Here, we presented a refractory pemphigus case combined with cancer, treated with telitacicept, a novel bioagent simultaneously targeting BLyS (B lymphocyte stimulator) and APRIL (a proliferation-inducing ligand),2 achieving complete remission without tumor progression or secondary skin infections. The gene discussed is TNFSF13B; the disease is pemphigus.